ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ КОРРЕКЦИИ АНЕМИИ У БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК

Д.А. Эгамбердиева. Ташкентский педиатрический медицинский институт

Резюме
Применение агентов, стимулирующих эритропоэз, позволяет достигать целевых значений гемоглобина и гема-
токрита у больных додиализных стадий ХБП.
Как показало наше исследование, ГЛЖ развивается уже в консервативных стадиях ХБП. При этом анемия
может выступать в качестве дополнительного патогенетического фактора в развитии ГЛЖ. Кроме того, была
подтверждена роль артериальной гипертензии как фактора риска ГЛЖ у больных ХБП, при этом выявлена связь
между ГЛЖ и уровнем САД, срАД, пульсового АД и возрастом больных.

Ключевые слова
хроническая болезнь почек, ренальная анемия, скорость клубочковой фильтрации, эхокардио-
графия.

Первая страница
45

Последняя страница
48

Для цитирования
Д.А. Эгамбердиева.Патогенетическое обоснование коррекции анемии у больных С хронической болезнью почек// Евразийский вестник педиатрии. — 2019; 2 (2): 45-48. https://cutt.ly/KcI3hoE

Литература

6. 1. Дзяк Г.В., Каплан П.А., Кардиоренальный синдром: патофизиология, верификация, подходы к лечению. «Почки» 2012; 01. [ Dzyak G.V., Kaplan P.A., Kardiorenal’nyy sindrom: patofiziologiya, verifikatsiya, podkhody k lecheniyu. «Pochki» 2012; 01. (In Russ) ].Клинические рекомендации. Научное общество нефрологов России, Ассоциация нефрологов России. Москва
7. 2. [Klinicheskiye rekomendatsii. Nauchnoye obshchestvo nefrologov Rossii, Assotsiatsiya nefrologov Rossii. Moskva (In Russ) ].
8. 3. Кобалава Ж.Д., Моисеев В.С. Концепция кардиоренальных и метаболических соотношений в современной профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2008; 4: 4-7. [Kobalava ZH.D., Moiseyev V.S. Kontseptsiya kardiorenal’nykh i metabolicheskikh sootnosheniy v sovremennoy profilakticheskoy kardiologii. Kardiovaskulyarnaya terapiya i profilaktika. 2008; 4: 4-7. (In Russ) ].
9. 4. Мухин Н.А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Терапевтический архив 2004;9:5-10. [Mukhin N.A., Balkarov I.M., Moiseyev V.S. i dr. Khronicheskiye progressiruyushchiye nefropatii i obraz zhizni sovremennogo cheloveka. Terapevticheskiy arkhiv 2004; 9: 5-10. (In Russ) ],
10. 5. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика, 2011; 10(6). Приложение 2. http://scardio.ru/ rekomendacii/rekomendacii_rko/ [Natsional’nyye rekomendatsii po kardiovaskulyarnoy profilaktike. Kardiovaskulyarnaya terapiya i profilaktika, 2011; 10(6). Prilozheniye 2. http://scardio. ru/rekomendacii/rekomendacii_rko/ (In Russ) ].
11. 6. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Смирнов А.В., Шилов Е.М., Добронравов В.А., Каюков И.Г., Бобкова И.Н., Швецов М.Ю., Цыгин А.Н., Шутов А.М. Нефрология. 2012; 16(1): 89-115. [Natsional’nyye rekomendatsii. Khronicheskaya bolezn’ pochek: osnovnyye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniyu. Smirnov A.V., Shilov Ye.M., Dobronravov V.A., Kayukov I.G., Bobkova I.N., Shvetsov M.YU., Tsygin A.N., Shutov A.M. Nefrologiya. 2012; 16(1): 89-115. (In Russ) ].
12. 7. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Национальные рекомендации. Москва. 2013. Serdechno-sosudistyy risk i khronicheskaya bolezn’ pochek: strategii kardio-nefroprotektsii. Natsional’nyye rekomendatsii. Moskva. 2013. (In Russ) ].
13. 8. Шилова Е.М. Хроническая болезнь почек и нефропротективная терапия. Методическое руководство для врачей. Под редакцией Е.М. Шилова. Москва. 2012. [Khronicheskaya bolezn’ pochek i nefroprotektivnaya terapiya. Metodicheskoye rukovodstvo dlya vrachey. Pod redaktsiyey Ye.M. Shilova. Moskva. 2012. (In Russ) ].
14. 9. Шутов А.М., Серов В.А. Кардиоренальный и ренокардиальный синдромы. Нефрология. 2009; 13(4): 59-63. [Shutov A.M., Serov V.A. Kardiorenal’nyy i renokardial’nyy sindromy. Nefrologiya. 2009; 13(4): 59-63. (In Russ)].
15. 10. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
16. 11. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
17. 12. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279–2289,
18. 13. Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G: Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant 2008; 23: 2879–2883,
19. 14. Daniel W, Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am SocNephrol 2007; 18: 975–984,
20. 15. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-701.
21. 16. Fishbane S, Pollack S, Feldman HI, Joffe MM: Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am SocNephrol 2009; 4: 57–61 [PMC free article].
22. 17. Fishbane S: Iron management in nondialysis-dependent CKD. Am J Kidney Dis 2007; 49: 736–743.
23. 18. Ford BA, Coyne DW, Eby CS, Scott MG: Variability of ferritin measurements in chronic kidney disease: Implications for iron management. Kidney Int 2008; 75: 104–110,
24. 19. Gotloib L, Silverberg D, Shostak A: Iron deficiency is a very common cause of anemia in chronic kidney insufficiency and can often be corrected with IV iron. J Nephrol 2006; 19: 161–167,
25. 20. Hörl WH: Adjunctive therapy in anaemia management. Nephrol Dial Transplant 2002; 17: 56–59,
26. 21. Hsu C-Y, McCulloch CE, Curham GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am SocNephrol 2002; 13: 2783–2786,
27. 22. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int, (Suppl) 2012; 2: 1-138.
28. 23. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft EC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26: 292–299, [PubMed] [Google Scholar].
29. 24. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH: The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am SocNephrol 2006; 1: 9-18.
30. 25. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141–149.
31. 26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int (Suppl.) 2013; 3: 1-150.
32. 27. Mircescu G, Gârneaţă L, Căpuçsă C, Ursea N: Intravenous iron supplementation for the treatment of anemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 120–124.
33. 28. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60(5): 850-886.
34. 29. Panesar A, Agarwal R: Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis 2002; 40: 924-931,
35. 30. Rahman MM, Dutta PK, Hoque M, Khan MIH, Banik D, Dutta AK, Hasan MU, Yunus EB, Yunus ABM, Rahman MJ: Evaluation of iron status by bone marrow iron stain and correlation with serum profile in chronic kidney disease (CKD). Journal of Bangladesh College of Physicians and Surgeons 2007; 25: 117–120.
36. 31. Rocha LA, Barreto DV, Barreto FC, Dias CB, Moysés R, Silva MR, Moura LA, Draibe SA, Jorgetti V, Carvalho AB, Canzianiet ME: Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am SocNephrol 2009; 4: 105-109.
37. 32. Ronco C, Bellomo R, McCullough PA. Cardiorenal syndromes in critical care. ContribNephrol. 2010;Basel, Karger, 2010; 165: 366.
38. 33. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. //Am J Kidney Dis 2008; 52: 897-906.
39. 34. Silverberg DS, MD, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. //Am J Kidney Dis 1996; 27: 234-238.
40. 35. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ: Ferumoxytol for treating iron deficiency anemia in CKD. J Am SocNephrol 2008.; 19: 1599-1605.
41. 36. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423.
42. 37. Van Wyck DB, Roppolo MO, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: 2846-2856.
43. 38. Wish JB: Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am SocNephrol 2006; 1[ Suppl 1]: 4-8,

Статья доступна ниже :